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Background: Acromegaly is usually caused by a benign pituitary tumour, with increased production of 
growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Treatment options include surgery, 
followed by pharmacological treatment with dopamine agonists, somatostatin analogues, GH receptor 
antagonists or radiotherapy. Treatment optimization is important to decrease the burden of this often-
chronic disease on the patient. 
 
Objectives: To evaluate the effectiveness in IGF-1 control of Lanreotide Autogel (LAN) 120 mg at 
extended dosing intervals (EDIs) (>4 weeks) in patients with acromegaly in routine clinical practice. 
Methods: Observational, retrospective study at 38 sites (36 Spanish, 2 Portuguese) (NCT02807233). 
Targeted enrolment was 100 adult patients diagnosed with acromegaly, receiving LAN 120 mg at EDIs 
for ≥6 months, with available data on treatment start/schedule and blood GH and IGF-1 assay 
immediately before study visit, and no radiation therapy in the 6 months preceding. The primary outcome 
was the percentage of patients with normalized IGF-1 level after at least 6 months of LAN treatment at 
prolonged doses. Secondary outcomes included percentages of patients with GH levels ≤2.5 ng/ml or ≤1 
ng/ml, and treated with EDIs of 5, 6, 7 or 8 weeks. Treatment satisfaction, quality of life (QoL) and 
treatment compliance were assessed. 
 
Results: Of 114 patients included, 109 were evaluable. Mean (±S.D.) age was 59.1 (±13.2) years. 69.7% 
had tumour resection performed on average 12.8 (±9.4) years ago. 25.7% received radiotherapy on 
average 17.9 (±9.4) years ago. 83.5% had comorbidities, with hypertension the most common (64.4%). 
77.1% had concomitant medication for conditions besides acromegaly. LAN had been the first-line 
pharmacological treatment for 67.0% of the patients. 91.7% had normalized IGF-1 values. 80.6% had GH 
levels ≤2.5 ng/ml, and 58.3% had levels ≤1 ng/ml. The EDIs most commonly used in routine clinical 
practice were 8 weeks (35.8%) and 6 weeks (37.6%). AcroQoL questionnaire showed that patients had a 
medium level of physical [59.7 (±24.5)] and psychological [64.9 (±20.1)] QoL. TQ10M-9 questionnaire 
revealed that patients were satisfied with treatment [75.1 (±16.6)], and considered it effective [70.6 
(±18.7)] and convenient [69.1 (±17.6)]. General therapeutic compliance during preceding 6 months was 
94.5%. 
 
Conclusions: LAN 120 mg at EDIs (>4 weeks) during at least 6 months provided IGF-1 control in more 
than 90% of patients with acromegaly, with good levels of treatment satisfaction and compliance. 
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